Kidney transplant recipients with type 2 diabetes treated with a new class of anti-obesity drugs were less likely to experience organ failure and survived longer, a new study shows.

Type 2 diabetes mellitus (T2DM) occurs when the body cannot use insulin properly, causing sugar to build up in the blood. T2DM is the type of diabetes you can "get" due to risk factors like obesity ...

About nine out of ten people with diabetes have type 2 diabetes. The good news is that type 2 diabetes can be prevented or postponed by making healthy lifestyle choices. Diabetes is a lifelong ...

Kidney transplant recipients with type 2 diabetes treated with a new class of anti-obesity ... now marketed as Ozempic, ...

Victoza (liraglutide) is a prescription drug used to help manage type 2 diabetes and reduce the risk of certain diabetes-related heart problems. Victoza is given as a daily injection under the skin.

Novo Nordisk’s GLP-1 agonist Victoza has become the first non-insulin drug to be approved in the US as a treatment for type 2 diabetes in children for almost two decades.

Insulin is a hormone that allows glucose in the blood to enter cells, providing them with the energy to function. A lack of adequate insulin plays a key role in the development of diabetes ...

The drugs selected for the report include Mounjaro, Rybelsus, Ozempic, Trulicity, Bydureon, Victoza, Byetta, Invokana, Jardiance and Farxiga. Currently, Medicare Part D covers diabetes drugs for ...